Dabigatran etexilate
- Generic Name
- Dabigatran etexilate
- Brand Names
- Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C34H41N7O5
- CAS Number
- 211915-06-9
- Unique Ingredient Identifier
- 2E18WX195X
- Background
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monit...
- Indication
Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to re...
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Venous Thromboembolism
- Associated Therapies
- -
Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06360055
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT06329895
- Locations
- 🇬🇧
PAREXEL International Early Phase Clinical Unit (London), Harrow, United Kingdom
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 6660
- Registration Number
- NCT05735639
- Locations
- 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05673889
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05480475
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT05471817
- Locations
- 🇩🇪
CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT05438303
- Locations
- 🇺🇸
Research Site, Berlin, New Jersey, United States
Fruquintinib DDI Study With P-gp and BCRP Substrates
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 32
- Registration Number
- NCT05368805
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05347979
- Locations
- 🇺🇸
Site 01, Miami, Florida, United States
A Study of Lasmiditan in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT04749914
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.